Form 483

Rafa Laboratories Ltd. Form 483, 2019-11-25

FDA issued a Form 483 to Rafa Laboratories Ltd. on 2019-11-25 with 12 public-safe observations.

483· Form 483 issuedHuman Drugs12 observations

Rafa Laboratories Ltd. · Jerusalem, Israel · Issued November 25, 2019

Overview

  • 12 public-safe observations are available for this inspection.
  • 6 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

25 Nov 2019
21 CFR 211.111

Establishment of time limitations

Cited by Saied A Asbagh

25 Nov 2019
21 CFR 211.111

Establishment of time limitations

Cited by Saied A Asbagh

25 Nov 2019
21 CFR 211.160(a)

Following/documenting laboratory controls

Cited by Saied A Asbagh

25 Nov 2019
21 CFR 211.160(a)

Following/documenting laboratory controls

Cited by Saied A Asbagh

25 Nov 2019
21 CFR 211.188

Prepared for each batch, include complete information

Cited by Saied A Asbagh

Inspected site

RLRafa Laboratories Ltd.Jerusalem, Israel

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.111Cited across public-safe Form 483 observations2x
21 CFR 211.160(a)Cited across public-safe Form 483 observations2x
21 CFR 211.188Cited across public-safe Form 483 observations2x
21 CFR 211.192Cited across public-safe Form 483 observations2x
21 CFR 211.42(c)(10)(iv)Cited across public-safe Form 483 observations2x
21 CFR 211.63Cited across public-safe Form 483 observations2x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 12 observations

The source PDF, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere